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This study was conducted to evaluate and compare the efficacy and safety of 
aprepitant in combination with dexamethasone, granisetron and metoclopramide 
(APR-DGM) versus a treatment regimen containing dexamethasone, granisetron and 
metoclopramide (DGM) as a prophylaxis in chemotherapy induced nausea and 
vomiting (CINV) in highly emetogenic chemotherapy in cancer patients. 
 
METHODS:  
A retrospective study, conducted in King Abdul-Aziz Medical city (Eastern Region, 
Saudi Arabia).  
Three hundred and nine patients, treated with highly emetogenic chemotherapy, were 
enrolled in a retrospective, single-center cohort study. This study is a cross sectional 
study for the period 2010-2014. The primary efficacy endpoint was the complete 
response (CR) for acute emesis (during the 0–24-hrs. interval after chemotherapy). 




The APR-DGM regimen showed a significantly improved control in the management 
of CINV in patients treated with highly emetogenic chemotherapy in acute emesis 
compared to the DGM regimen (P= 0.0021). No significant difference was observed 
between the two regimens with regards to delayed emesis (P= 0.145). Both groups 
were tolerated well, and the rates of adverse events were not significantly different 
between groups. 
DISCUSSION:  
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The addition of aprepitant to the standard regimen of dexamethasone, granisetron and 
metoclopramide was found to be significantly better than dexamethasone, granisetron 
and metoclopramide alone in the control of acute emesis, but with no significant 
change in delayed emesis. This study therefore supports the change of regimen in the 
management of acute emesis with highly emetogenic chemotherapy to include 
aprepitant. 
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According to the world statistics, 14.1 million adults in the world were diagnosed with cancer in 
2012 and 8.2 million deaths resulted from cancer in the world in the same year.
1
 Therefore a lot of 
research is directed towards the treatment of cancer and the management of related side effects of 
chemotherapy. Although there are many side effects associated with chemotherapy, chemotherapy-
induced nausea and vomiting (CINV) is considered an extreme side effect that affects the quality of 




     1.1 Background and rationale for this study 
 
CINV is one of the greatest sources of distress for patients. Because severe CINV may force 
interruption of chemotherapy, it is important to control CINV to achieve successful chemotherapy. 
Emesis are classified according to the two following major types: 1) acute emesis is vomiting that 
occurs during the first 18-24 hours after chemotherapy administration with peak occurring at 4 - 6 
hours depending on the agent given and 2) delayed emesis with vomiting occurring > 18-24 hours 
after chemotherapy administration, but may occur up to 5 days after chemotherapy with the peak in 
2 to 3 days.
3




In patients treated with highly emetogenic chemotherapy, 60% experience delayed nausea, and 50% 
experience delayed emesis. In patients treated with moderately emetogenic chemotherapy, 52% 
experience delayed nausea, and 28% experience delayed emesis.
4
 At the 2009 MASCC / ESMO 
Consensus Conference, an expert panel used data to establish rankings of emetogenicity for 
chemotherapy agents.
5
 Oral chemotherapy agents are now ranked separately from IV agents as 






The most problematic effects caused by CINV are dehydration, malnutrition, metabolic imbalances, 
and potential withdrawal from future cycles of chemotherapy. 
 
      1.2      Research questions 
 
This study will determine the efficacy and safety of aprepitant by comparing two treatment 
regimens for prophylaxis of CINV: 
Regimen 1: patients treated with the antiemetic regimen DGM containing Dexamethasone (D), 
Granisetron (G) and Metoclopramide (M).  
Regimen 2: patients treated with APR –DGM containing Aprepitant (APR), Dexamethasone (D), 
Granisetron (G) and Metoclopramide (M). 
 
1.3 Aims and objectives for this study 
 
The aim of this study is to determine if aprepitant is safe and effective by comparing aprepitant in 
combination with DGM as a prophylaxis of CINV to the DGM regimen (without aprepitant) as 
prophylaxis of CINV in highly emetogenic chemotherapy . 
 
Objectives of the study:  
Primary objectives 
1-Efficacy of aprepitant: 
The primary end point is to evaluate the acute emesis within 24 hours after administration of 
chemotherapy (0-24 hours) by using complete response (CR): no emesis, no admission because of 
emesis and no rescue therapy needed. 
Efficacy of aprepitant will be determined by comparing the incidence of acute emesis (0-24 hr.) in 
regimen 1 (DGM) vs regimen 2 (APR-DGM) via the following: 
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a)   Cases with emesis. 
b) Administration of antiemetic rescue medication including metoclopramide, lorazepam, 
granisetron or dexamethasone. 
 
c)   Hospital admissions due to CINV 
 
2-Safety of the aprepitant: 
Determine the observed adverse drug events in the regimen 1 (DGM) compared to regimen 2 
(APR-DGM). 
 
The secondary objective: 
The secondary end point is the proportion of patients with a complete response (CR), no emesis or 
use of rescue therapy, after the administration of chemotherapy in delayed (24 -120 hours) phase of 
emesis. 
1-Evaluate the incidence of delayed emesis (25-120 hours) in regimen 1 (DGM) 25-120 hours after 
administration of chemotherapy compared to regimen 2 (APR-DGM) 25-120 hours after   
administration of chemotherapy. 
 
     1.4   Significance and Novelty of the study: 
 
The efficacy and safety of aprepitant added to dexamethasone, metoclopramide and granisetron 
have not been studied before as most studies included aprepitant added to dexamethasone and 5HT3 
antagonists e.g. granisetron only, without using metoclopramide.  
Most of retrospective studies have been done on cisplatin and anthracycline; this study will be an 
exploratory retrospective study assessing the efficacy and safety of aprepitant with a chemotherapy 




      1.5 Research Methodology 
 
1.5.1 Study design 
 
This study was designed as a retrospective medical chart review, analytic, single-center study using 
309 patients, conducted at National Guard Hospital in King Abdul-Aziz Medical city (Eastern 
Region, Saudi Arabia). 
The study population consisted of cancer patients treated with a highly emetogenic regimen 
containing 1) anthracycline like doxorubicin, epirubicin and cyclophosphamide as treatment for 
breast cancer and NHL (Non Hodgkin Lymphoma), and 2) dacarbazine in HL (Hodgkin 
Lymphoma) in the period from April 2010 till the end of 2014. 
The chemotherapy regimens used were: 
Breast cancer protocols 
1- AC: intravenous doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, CAF: intravenous 
doxorubicin 50 mg/m
2
, cyclophosphamide 500 mg/m
2
, and fluorouracil 500 mg/m
2
. 







3-  RCHOP (Rituximab 375 mg/m2 Doxorubicin 50 mg/m2 Cyclophosphamide 750 mg/m2 
Vincristine 1.4mg/m
2
 ,Prednisone 45 mg/m
2
 PO or Methylprednisolone 125 mg IV ). 





These protocols have high risk of emesis and cause nausea and vomiting in more than 90% of 






1.5.2  Data source 
 
Data was extracted from electronic charts and nurse’s notes for 308 patients - 156 in DGM group and 153 
APR-DGM group. Data was reviewed by one reviewer and verified by an additional reviewer. All data was 
collected in Excel and contained all variables including demographic data such as age, nationality, race, 
gender, surface area and performance of the patient according to ECOG, and clinical characteristics like type 
of cancer, name of protocols and number of courses taken. 
 
To measure CR, the data collected included early emesis, late emesis, use of rescue medication 
(acute phase and early phase) and number of hospital admission.    
 
Review of the patient file and safety reporting system (SRS) were used to extract all information 
related to adverse event(s), drug-related adverse event(s), or serious adverse event(s). National 
Cancer Institute (NCI) toxicity criteria (version 3.0) were used to assign toxicity grades. 
 
1.5.3 Data analysis 
 
The primary objective was to determine efficacy of aprepitant by evaluating the incidence of acute 
emesis (0-24 hr.) in both treatment groups. The primary end point was the proportion of patients 
with a complete response (no emesis, no admission or use of rescue therapy) after the 
administration of chemotherapy in 0–24-hours. 
 
The second primary objective was to determine the safety of the aprepitant. This was done by 
evaluating the incidence of delayed emesis (25-120 hours) in both treatment groups.  
 
300 patients were required to achieve 80% statistical power by using two Independent Proportions 
(Null Case) Power Analysis. The test statistic used was the two-sided Z test with continuity 
correction and unpooled variance. The significance level of the test was targeted at 0.05. Baseline 
patient demographics and clinical characteristics as well as safety data were summarized using 
descriptive statistics. Descriptive summary statistics are presented for each of the efficacy 
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parameters. Chi square tests of independence were performed on nominal variables and used to 
determine the CR. All statistical tests were two-sided, and p < 0.05 was considered significant. Data 
was coded and analysis into SPSS for statistical analysis IBM SPSS software version, 20.  
 
1.5.4  Data Management 
 
Data was collected from the patient medical records and electronic system. Raw data was imported 
in Excel. The primary investigator requested access to use and extract data as per the policy of the 
institution. 
 
1.5.5  Ethical approval 
 
Full ethical approval for the study was obtained from the Humanities and Social Sciences Research 
Ethics Committee of the University of KwaZulu-Natal (REC-290408-009) 6 May 2016 – 
(Annexure 1), and from the Investigational Review Board KAIMRC Research Office - King 
Abdullah International Medical Research Center  under Subject RA15/002/A - "Efficacy and safety 
of Aprepitant as a prophylaxis of CINV in highly emetogenic level of chemotherapy in combination 
with Dexamethasone, Granisetron and Metoclopramide (DGM)". 
 
No patient hospital numbers, names/surnames/initials/ or date of birth/identification numbers were 
reported in the data sets, hence, patient confidentiality was maintained at all times.  
The study was conducted in accordance with the principles of the Declaration of Helsinki and its 
amendments and in compliance with International Conference on Harmonization, Good Clinical 
Practices, and all applicable regulatory guidelines. 
 
1.6 Chapter summary   
 
This chapter provided a background and rationale of the study. It also included the aims, objectives, 
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2. MANUSCRIPT FOR SUBMISSION AND PUBLICATION 
 
2.1 Introduction 
This chapter describes the general findings and discussion of the results of the study and is 
represented in the form of a manuscript titled “Efficacy and safety of aprepitant in combination with 
dexamethasone, granisetron and metoclopramide as prophylaxis for chemotherapy-induced nausea 
and vomiting’’ This manuscript will be submitted to the “The Cancer Journal” for publication. 
http://www.ICMJE.org. 
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This study was conducted to evaluate and compare the efficacy and safety of aprepitant in a 
treatment regimen containing aprepitant in combination with dexamethasone, granisetron and 
metoclopramide (APR-DGM) versus a regimen containing dexamethasone, granisetron and 
metoclopramide (DGM) only as a prophylaxis in chemotherapy induced nausea and vomiting 
(CINV) in highly emetogenic chemotherapy in cancer patients. 
 
METHODS:  
Three hundred and nine patients, treated with highly emetogenic chemotherapy, were enrolled in a 
retrospective, single-center cohort study to investigate the efficacy and safety of aprepitant in 
combination with dexamethasone, granisetron and metoclopramide (APR-DGM) compared to 
dexamethasone, granisetron and metoclopramide (DGM) without aprepitant. This study is a cross 
sectional study for the period 2010-2014. The primary efficacy endpoint was the complete response 
(CR) for acute emesis (during the 0–24-hrs. interval after chemotherapy). Secondary endpoint was 
the CR rates for delayed emesis (during the 24 hrs. -120 hrs. after chemotherapy). 
 
RESULTS:  
The APR-DGM regimen showed a significantly improved control in the management of CINV in 
patients treated with highly emetogenic chemotherapy in acute emesis compared to the DGM 
regimen (P= 0.0021). No significant difference was observed between the two regimens with 
regards to delayed emesis (P= 0.145). Both regimens were well tolerated, and the rates of adverse 




DISCUSSION:   
The addition of aprepitant to the standard regimen of dexamethasone, granisetron and 
metoclopramide was found to be significantly better than dexamethasone, granisetron and 
metoclopramide alone, but only in the control of acute emesis, with no significant change in 
delayed emesis. This study therefore supports the change of regimen in the management of acute 
with highly emetogenic chemotherapy to include aprepitant. 
 



















CINV is a common adverse event in cancer therapy. Because CINV has a strong negative influence 
on patient quality of life (QOL), CINV management is highly important.  
 
Chemotherapeutic agents are generally classified by their emetogenic effects, namely, “highly 
emetogenic chemotherapy” (HEC), “moderately emetogenic chemotherapy” (MEC), and “lower-





The triple antiemetic therapy, using a 5-HT3 receptor antagonist, dexamethasone, and a neurokinin-
1 (NK1) receptor antagonist, is the established and recommended treatment for HEC regimens. This 





While the majority of trials in literature have studied triple medication including dexamethasone, 
granisetron and aprepitant for prophylaxis of CINV, the aim of this study was to compare  
aprepitant in combination with DGM as a prophylaxis of CINV to the DGM regimen (without 
aprepitant) as prophylaxis of CINV in highly emetogenic chemotherapy 
 
   Method  
Study design 
This study was designed as a retrospective medical chart review, single-center study, conducted at 
the National Guard Hospital in King Abdul-Aziz Medical city (Eastern Region, Saudi Arabia). The 
study population consisted of cancer patients treated with a highly emetogenic regimen as treatment 
for either breast cancer, lymphoma NHL (Non Hodgkin Lymphoma) or HL (Hodgkin Lymphoma), 
in the period from April 2010 till the end of 2014.  
 
The HEC protocols included: 
Breast cancer protocols: 
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AC: intravenous doxorubicin 60 mg/m
2
 and cyclophosphamide 600 mg/m
2 
CAF: intravenous doxorubicin 50 mg/m
2
, cyclophosphamide 500 mg/m
2
, and fluorouracil 500 
mg/m
2
 ,  
CEF: intravenous epirubicin 100 mg/m
2





RCHOP (rituximab 375 mg/m
2





 ,prednisone 45 mg/m
2
 PO or methylprednisolone 125 mg IV ) 
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ABVD (doxorubicin 25 mg/m
2
 vinblastine 6 mg/m
2
 bleomycin 10 mg/m
2






This study received approval from the Investigational Review Board KAIMRC Research Office - 
King Abdullah International Medical Research Center under Subject RA15/002/A - "Efficacy and 
safety of Aprepitant as a prophylaxis of CINV in highly emetogenic level of chemotherapy in 
combination with Dexamethasone, Granisetron and Metoclopramide (DGM)". Full ethical approval 
for the study was obtained from the Biomedical Research Ethics Committee of the University of 
KwaZulu-Natal (BE050/1).  
 
The study was conducted in accordance with the principles of the Declaration of Helsinki and its 
amendments and in compliance with International Conference on Harmonization, Good Clinical 




309 Subjects were selected for inclusion in the study; this included 156 in group DGM and 153 in 
group APR-DGM. 
Inclusion criteria: 
 Patients aged between 18 to 75 years. 
 Chemotherapy naïve patients (have not received chemotherapy before). 
 Patients diagnosed with breast cancer stage II, III, IV or lymphoma stage II, III, IV . 
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 Patients who failed on standard antiemetic therapy with a 5HT3 antagonist plus dexamethasone      
for moderately emetogenic regimens. 
 Patients with performance statues Eastern Cooperative Oncology Group (ECOG SCORE) less 
than 5. 
Exclusion criteria: 
 Hypersensitivity to aprepitant/fosaprepitant, polysorbate 80 or any ingredients in the 
formulation. 
 Patients on concurrent pimozide or cisapride (aprepitant is a weak to moderate dose-dependent 
inhibitor of CYP3A4 and therefore contraindicated for use with terfenadine, astemizole cisapride, 
or pimozide (concurrent use may result in life threatening reactions)). 
 Chemotherapy regimens with minimal, low, or moderate potential for incidence of 
emetogenicity. 
 Pregnant and lactating woman. 
 Patients with any psychological problems. 




DGM treatment group: 156 patient charts for the period April 2010 to April 2012, were selected. 
The DGM regimen was administered according to Table 1.  
 
DGM-APR treatment group: 153 patient charts for the period May 2012 till the end of year 2014 
were selected. The DGM –APR regimen were administered according to Table 2.  
 



















16 mg IVB in 50 
ml normal 0.9 
saline before 
chemotherapy 30 
















8 mg  twice 
daily 
 
Dexamethasone 8 mg  
twice daily 
 
Granisetron 1 mg 
IVB in 50 ml 
normal 0.9 saline 
before 
chemotherapy 30 




Twice  daily 
Granisetron 2 




Twice  daily 
Granisetron 2 mg PO 
Twice  daily 
Metoclopramide 1 
0 mg 
IVB in 50 ml 
normal 0.9 saline 
before 
chemotherapy 30 
mins infused over 




10 mg Every 6 
hours and PRN 
Metoclopramide 
10 mg Every 6 
hours and PRN 
Metoclopramide 
10 mg 
Every 6 hours 
and PRN 
Metoclopramide 10 
mg Every 6 hours and 
PRN 
 

















Aprepitant 125 mg 
Before chemotherapy 45-60 mins 
 
Aprepitant 80 mg 
 
Aprepitant 80 mg 
 
 
Dexamethasone 12 mg IVB in 50 
ml normal 0.9 saline before 
chemotherapy 30 mins infused 
over 30 mins 
 
Dexamethasone 8 








oral once daily 
 
Granisetron 1 mg IV mg IVB in 
50 ml normal 0.9 saline before 
chemotherapy 30 mins infused 
over 5 mins 
 
   
 
Metoclopramide 10 mg 
IVB in 50 ml normal 0.9 saline 
before chemotherapy 30 mins 














Every 6 hours 
and PRN 
 
It is important to note that dexamethasone should not be added to a chemotherapeutic regimen that 
already contains corticosteroids; therefore, in the RCHOP protocol used for treatment of Non 
Hodgkin Lymphoma, dexamethasone was omitted. Methyl prednisolone 125 mg, as part of RCHOP 
protocol, can cover acute and delayed emesis. 
Outcomes and Statistical analysis 
 
The test statistic used was the two-sided Z test with continuity correction and unpooled variance. 
The significance level of the test was targeted at 0.05. Baseline patient demographics and clinical 
characteristics as well as safety data were summarized using descriptive statistics. Descriptive 
summary statistics are presented for each of the efficacy parameters. Chi square tests of 
independence were performed on nominal variables and used to determine the CR. All statistical 
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tests were two-sided, and p < 0.05 was considered significant. All statistical analyses were 






A total of 309 patient files were analysed, 156 receiving regimen DGM (50.49%) and 153 receiving 
regimen APR-DGM (49%). The majority of patients were Arabic 298 (96.44%) and only 
11(3.56%) non-Arabic. Most patients were Saudi 290 (93.85%) vs 19 (6.15% non-Saudi). 
 
205 from the 309 cases were female (66.34%). 60% female patients (94/156) were on the DGM 
regimen, and 71% (111/153) on the APR-DGM regimen. 33.66% male patients (62/156) were on 
the DGM regimen and 42/153 (27%) on the APR-DGM regimen (table 3). 
 
Patients with surface area equal to 2 were 263 (85.11%) and patient with surface area equal to 1 was 
46 (14.89%). Performance statues of the patient according to ECOG score was 267 with 0 score 
(86.41%), 32 (10.36%) with score 1 and 10 (3.24%) with score 2. The mean age of the population 
was 47.3 ±4.7. 
 
EFFICACY  
The results show a statistically significant difference in complete response (no emesis, no admission 
and no use of rescue therapy) in acute emesis when comparing the two treatment regimens (p-value 
0.002). The number of emesis in acute phase was statistically significantly lower in the APR-DGM 
group compared to the DGM group (p-value 0.0021).  
 
The need for rescue medication was also statistically significantly in acute phase (p-value 0.001).    




No statistical significant differences between the two regimens were observed in the management of 
delayed emesis (p-value 0.145). The need for rescue medication when receiving treatment with the 
two different regimens also showed no statistically significance in the delayed phase (p-value 
0.075). The numbers of hospital admission between two groups have been decreased (p-value 
0.013). (See table 3). 
 
Table 3: Univariate analysis for early and late emesis per each group (N =309) 
 























































































































Safety and tolerability of the two treatment regimens were assessed and compared through clinical 
review of safety parameters using Chi-Square. Treatment comparisons were made with respect to 
the P- value and the proportion of patients who reported one or more adverse event(s), drug-related 
adverse event(s), or serious adverse event(s).  
 
All side effects observed in both regimens were tolerable and manageable. The rates for frequently 
observed ADEs were not significantly different between the two regimens. None of the patients 
experienced severe toxicities. (See table 4) 
 
Table 4 Adverse events (N = 309) 
 


































9    (5.77) 
147(94.23) 
 













7    (4.49) 
149(95.51) 
 













20  (12.82) 
136(87.18) 
 













4    (2.56) 
152(97.44) 
 














13  (8.3) 
143(91.67) 
 













15   (9.62) 
141 (90.38) 
 












12   (7.69) 
144 (92.31) 
 
4      (2.61) 












13   (8.3) 
143 (91.67) 
 













2     (1.28) 
154 (98.72) 
 













17   (10.90) 
139 (89.1) 
 





























10  (6.4) 
146(93.59) 
 













20  (12.8) 
136(87.18) 
 













12  (7.69) 
144(92.31) 
 













5     (3.21) 
151(69.79) 
 









12  (7.69) 
 
































13    (8.31) 
143(91.78) 
 
































This study found that the APR-DGM regimen protected approximately 95% of patients from acute 
emesis after receiving highly emetogenic chemotherapy and enabled them to avoid the use of rescue 
therapy. This regimen also decreased the number of hospital admission due to CINV in the acute 
phase.  
 
The addition of aprepitant to a standard therapy regimen consisting of a granisetron plus 
dexamethasone and metoclopramide improved the control of CINV associated with highly 
emetogenic chemotherapy in the acute phase. The aprepitant regimen was generally well tolerated, 
with adverse events similar to those associated with DGM regimen.   
 
The time course and magnitude of improved control of emesis achieved with aprepitant support the 
hypothesis that superior control of CINV involves the blockade of substance P-mediated nausea and 
vomiting. The vomiting center in the medulla called the area postrema contains high concentrations 
of substance P and its receptor, in addition to other neurotransmitters such as choline, histamine, 
dopamine, serotonin, and opioids. Their activation stimulates the vomiting reflex. Different emetic 





 Substance P is a member of a group of peptides known as tachykinins; these 
tachykinins bind to neurokinin-1, 2, and 3 receptors. NK1 receptors are found throughout the 
central nervous system, including the area postrema and nucleus tractus solitarius and NK1 
receptors are also found in the GI tract. Aprepitant mediates the  effect of substance P by blocking 




In this study, it showed there was no significant difference in the response of DGM versus APR-
GM in delayed phase emesis. Delayed vomiting occurs after treatment with many anticancer drugs, 
but has been most often studied following cisplatin or combinations of cyclophosphamide and 




In the treatment of delayed emesis in non-cisplatin chemotherapy, corticosteroids and 5-HT3 
receptor antagonists are considered the most useful agents.
19
 Dexamethasone has consistently 
shown its antiemetic efficacy for delayed emesis induced by cisplatin and non-cisplatin agents, 
whereas the role of 5-HT3 antagonists alone remains controversial. Metoclopramide, the dopamine 
receptor antagonist, has been shown to be as efficacious as 5-HT3 antagonists when combined with 
dexamethasone for the prevention of delayed emesis[14]. Corticosteroids have synergistic effect  




In conclusion, aprepitant represents an important medical advance that can substantially enhance 
the supportive care of patients with cancer who receive highly emetogenic chemotherapy in acute 
phase but little support in delayed phase. The aprepitant regimen was generally well tolerated. Both 
DGM or APR-DGM can be recommended in delayed phase of emesis, but because of the lower 
cost of DGM should be chosen as prophylaxis for delayed emesis 
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  3.1.     Introduction 
 
This study was carried out to evaluate the safety and efficacy of aprepitant by comparing aprepitant 
in combination with DGM as a prophylaxis of CINV to the DGM regimen (without aprepitant) in 
highly emetogenic chemotherapy. 
 
 3.2 Strengths of the study methodology and design 
 
Data collection was cost-effective as the data sets used in the study were obtained from electronic 
medical records and stored as a Microsoft Excel document. The data was easy to analyze using 
IBM SPSS Statistics 20, considering that it was quantitative and obtained in the form of an 
extraction sheet and made available electronically. 
 
       3.3     Conclusions drawn from the study findings 
 
This study determined the efficacy and safety of aprepitant by comparing two treatment regimens 
for prophylaxis of CINV. The first regimen was the antiemetic regimen DGM containing 
Dexamethasone (D), Granisetron (G) and Metoclopramide (M). The second regimen was APR –
DGM containing Aprepitant (APR), Dexamethasone (D), Granisetron (G) and Metoclopramide 
(M). 
Conclusions drawn from the study findings based on each of these objectives.  
The primary objective was to determine the efficacy and safety of aprepitant by comparing the 
incidence of acute emesis (0-24 hr.) in regimen 1 (DGM) vs regimen 2 (APR-DGM) via the 
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following a) Cases with emesis; b) Administration of antiemetic rescue medication 
(Metoclopramide 10-20 mg, Lorazepam, Granisetron or Dexamethasone); c) The hospital 
admissions due to CINV (chemotherapy induces nausea and vomiting). The APR-DGM regimen 
showed a significantly improved control in the management of CINV in patients treated with highly 
emetogenic chemotherapy in acute emesis compared to the DGM regimen (P= 0.0021).  
Safety of the aprepitant was determined by the observed adverse drug events in the regimen 1 
(DGM) compared to regimen 2 (APR-DGM). Both regimens were well tolerated, and the rates of 
adverse events were not significantly different between the regimens. 
The secondary objective was to determine the efficacy of aprepitant in delayed phase of emesis and 
the secondary end point is the proportion of patients with a complete response (CR; no emesis or 
use of rescue therapy) after the administration of chemotherapy (25 -120 hours). No significant 
difference was observed in the management of delayed emesis between the two regimens (P= 
0.145). 
 
      3.4    Significance of the study 
 
The efficacy and safety of aprepitant added to dexamethasone, metoclopramide and granisetron 
have not been studied before as most studies done included only aprepitant added to dexamethasone 
and a 5HT3 antagonist e.g. granisetron, without using metoclopramide as a premedication.  
All retrospective studies have been done on cisplatin and only one study evaluated aprepitant as 
CINV for patient treated with an anthracycline containing regimen; there is therefore a lack of 
knowledge regarding treatment with a aprepitant-containing regimen for AC treatment of cancer.  
This study was an exploratory retrospective study assessing the effectiveness and safety of DGM in 
combination with aprepitant for CINV in highly emetic chemotherapy regimens compared to DHM 
alone amongst Arabic people.  




As data were obtained from patient medical records and not via direct patient interaction, some 
information was not available. 
1- Alcohol consumption is a very important factor and can have an effect on the risk of CINV. 
Alcoholic consumption can decrease the CINV. This type of information is considered as personal 
information in the study population, therefore not all patients may be willing to provide accurate 
information on this type of questions, so the reported information may not precise.
22
  
2- If a patient has motion sickness. People with history of motion sickness have high risk for CINV. 
3-Patients with depression are more susceptible for emesis than normal persons. Despite excluding 
these patients some patients included in the study population might still have undiagnosed patients 
with depression. Cancer itself can affect psychological status of the patients, and can cause 
depression. 
4-Any psychological factor like distress, anxiety can also effect on CINV, and is considered a 
difficult factor to be evaluated especially because it is a retrospective study.
23
 
5-The amount of sleep before the day of chemotherapy can affect CINV, and this factor is 
considered a very difficult to determine or assess. 
6- The sample size is considered small which can affect the power of the study. 
 
3.6       Recommendations 
 
For AC-regimens, both the 5-HT3 and NK1-sensitive mechanism appear to be important in the 
initial phase; NK1 effects have the greatest impact with the first 12 hours after chemotherapy .
19,24
.  
Using 5HT3 for covering delay emesis with aprepitant need more study.DGM or APR-DGM can be 
recommended in delayed phase of emesis, but because of the      lower cost of DGM should be 
chosen as prophylaxis for delayed emesis. 
Delayed emesis because of CINV need more studies with different chemotherapy regimens. 
Adding metoclopramide with low doses with aprepitant in all phases of chemotherapy needs more 
study. 
 




The final chapter highlighted the conclusions drawn from the findings of the study, described the 
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